Comparative Immunogenicity of Enhanced Seasonal Influenza Vaccines in Older Adults: A Systematic Review and Meta-analysis

BACKGROUND A number of enhanced influenza vaccines have been developed for use in older adults, including high-dose, MF59-adjuvanted, and intradermal vaccines. METHODS We conducted a systematic review examining the improvements in antibody responses measured by the hemagglutination inhibition assay associated with these enhanced vaccines, compared with each other and with the standard-dose (SD) vaccine using random effects models. RESULTS Thirty-nine trials were included. Compared with adults aged ≥60 years receiving SD vaccines, those receiving enhanced vaccines had significantly higher postvaccination titers (for all vaccine strains) and higher proportions with elevated titers ≥40 (for most vaccine strains). High-dose vaccine elicited 82% higher postvaccination titer to A(H3N2) compared with SD vaccine; this was significantly higher than the 52% estimated for MF59-adjuvanted versus SD vaccines (P = .04), which was higher than the 32% estimated for intradermal versus SD vaccines (P < .01). CONCLUSIONS Overall, by summarizing current evidence, we found that enhanced vaccines had greater antibody responses than the SD vaccine. Indications of differences among enhanced vaccines highlight the fact that further research is needed to compare new vaccine options, especially during seasons with mismatched circulating strains and for immune outcomes other than hemagglutination inhibition titers as well as vaccine efficacy.

[1]  Sang-Moo Kang,et al.  Immunology and efficacy of MF59-adjuvanted vaccines , 2018, Human vaccines & immunotherapeutics.

[2]  A. Chit,et al.  Efficacy and effectiveness of high-dose versus standard-dose influenza vaccination for older adults: a systematic review and meta-analysis , 2018, Expert review of vaccines.

[3]  S. Pillet,et al.  The establishment of surrogates and correlates of protection: Useful tools for the licensure of effective influenza vaccines? , 2018, Human vaccines & immunotherapeutics.

[4]  P. Pitisuttithum,et al.  Immune responses to intradermal and intramuscular inactivated influenza vaccine among older age group. , 2017, Vaccine.

[5]  A. Levêque,et al.  Effectiveness of influenza vaccines in preventing severe influenza illness among adults: A systematic review and meta-analysis of test-negative design case-control studies. , 2017, The Journal of infection.

[6]  C. Rizzo,et al.  Repeated seasonal influenza vaccination among elderly in Europe: Effects on laboratory confirmed hospitalised influenza. , 2017, Vaccine.

[7]  M. Cox,et al.  Efficacy of Recombinant Influenza Vaccine in Adults 50 Years of Age or Older , 2017, The New England journal of medicine.

[8]  Edward A Belongia,et al.  Repeated annual influenza vaccination and vaccine effectiveness: review of evidence , 2017, Expert review of vaccines.

[9]  R. Zarychanski,et al.  Efficacy and safety of high-dose influenza vaccine in elderly adults: A systematic review and meta-analysis. , 2017, Vaccine.

[10]  S. Hensley,et al.  Immune history and influenza virus susceptibility. , 2017, Current opinion in virology.

[11]  A. Domnich,et al.  Effectiveness of MF59-adjuvanted seasonal influenza vaccine in the elderly: A systematic review and meta-analysis. , 2017, Vaccine.

[12]  J. Noh,et al.  Immunogenicity and safety of a 13-valent pneumococcal conjugate vaccine and an MF59-adjuvanted influenza vaccine after concomitant vaccination in ⩾60-year-old adults. , 2017, Vaccine.

[13]  A. Chit,et al.  Fluzone® High-Dose Influenza Vaccine , 2016, Expert review of vaccines.

[14]  P. van Damme,et al.  A phase 1, open-label, randomized study to compare the immunogenicity and safety of different administration routes and doses of virosomal influenza vaccine in elderly. , 2016, Vaccine.

[15]  Judith M. Fonville,et al.  The confounded effects of age and exposure history in response to influenza vaccination. , 2016, Vaccine.

[16]  C. Diazgranados,et al.  Correlates of Protection against Influenza in the Elderly: Results from an Influenza Vaccine Efficacy Trial , 2016, Clinical and Vaccine Immunology.

[17]  F. Takeshita,et al.  Superior immunogenicity profile of the new intradermal influenza vaccine compared to the standard subcutaneous vaccine in subjects 65 years and older: A randomized controlled phase III study. , 2015, Vaccine.

[18]  F. Takeshita,et al.  Immunogenicity and safety of the new intradermal influenza vaccine in adults and elderly: A randomized phase 1/2 clinical trial. , 2015, Vaccine.

[19]  W. Ndifon.  A simple mechanistic explanation for original antigenic sin and its alleviation by adjuvants , 2015, Journal of The Royal Society Interface.

[20]  A. Monto,et al.  Antibody to Influenza Virus Neuraminidase: An Independent Correlate of Protection. , 2015, The Journal of infectious diseases.

[21]  A. Bianco,et al.  Immunogenicity and Safety of Intradermal Influenza Vaccine in the Elderly: A Meta-Analysis of Randomized Controlled Trials , 2015, Drugs & Aging.

[22]  J. Noh,et al.  Immunogenicity and safety of concomitant MF59-adjuvanted influenza vaccine and 23-valent pneumococcal polysaccharide vaccine administration in older adults. , 2015, Vaccine.

[23]  D. Nace,et al.  Randomized, controlled trial of high-dose influenza vaccine among frail residents of long-term care facilities. , 2015, The Journal of infectious diseases.

[24]  A. Domnich,et al.  Flucelvax (Optaflu) for seasonal influenza , 2015, Expert review of vaccines.

[25]  Thomas MaCurdy,et al.  Comparative effectiveness of high-dose versus standard-dose influenza vaccines in US residents aged 65 years and older from 2012 to 2013 using Medicare data: a retrospective cohort analysis. , 2015, The Lancet. Infectious diseases.

[26]  M. Basileo,et al.  Immunogenicity of intramuscular MF59-adjuvanted and intradermal administered influenza enhanced vaccines in subjects aged over 60: A literature review , 2015, Human vaccines & immunotherapeutics.

[27]  P. Shekelle,et al.  Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015 statement , 2015, Systematic Reviews.

[28]  S. Frey,et al.  Comparison of the safety and immunogenicity of an MF59®-adjuvanted with a non-adjuvanted seasonal influenza vaccine in elderly subjects. , 2014, Vaccine.

[29]  John Earl,et al.  Efficacy of high-dose versus standard-dose influenza vaccine in older adults. , 2014, The New England journal of medicine.

[30]  Kwok-Hung Chan,et al.  Immunogenicity and safety of intradermal trivalent influenza vaccination in nursing home older adults: a randomized controlled trial. , 2014, Journal of the American Medical Directors Association.

[31]  K. To,et al.  Immunogenicity of intradermal trivalent influenza vaccine with topical imiquimod: a double blind randomized controlled trial. , 2014, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[32]  I. Donatelli,et al.  Antibody responses to intradermal or intramuscular MF59-adjuvanted influenza vaccines as evaluated in elderly institutionalized volunteers during a season of partial mismatching between vaccine and circulating A(H3N2) strains , 2014, Immunity & Ageing.

[33]  W. Choi,et al.  Comparison of the Immunogenicity and Safety of the Conventional Subunit, MF59-Adjuvanted, and Intradermal Influenza Vaccines in the Elderly , 2014, Clinical and Vaccine Immunology.

[34]  C. Diazgranados,et al.  Immunogenicity and safety of Fluzone(®) intradermal and high-dose influenza vaccines in older adults ≥65 years of age: a randomized, controlled, phase II trial. , 2014, Vaccine.

[35]  Michael Worobey,et al.  Genesis and pathogenesis of the 1918 pandemic H1N1 influenza A virus , 2014, Proceedings of the National Academy of Sciences.

[36]  G. Leroux-Roels,et al.  A dose-ranging study in older adults to compare the safety and immunogenicity profiles of MF59®-adjuvanted and non-adjuvanted seasonal influenza vaccines following intradermal and intramuscular administration , 2014, Human vaccines & immunotherapeutics.

[37]  D. Skowronski,et al.  Low 2012–13 Influenza Vaccine Effectiveness Associated with Mutation in the Egg-Adapted H3N2 Vaccine Strain Not Antigenic Drift in Circulating Viruses , 2014, PloS one.

[38]  Anne M Johnson,et al.  Comparative community burden and severity of seasonal and pandemic influenza: results of the Flu Watch cohort study , 2014, The Lancet Respiratory Medicine.

[39]  E. Brodkin,et al.  The comparative effectiveness of adjuvanted and unadjuvanted trivalent inactivated influenza vaccine (TIV) in the elderly. , 2013, Vaccine.

[40]  L. Grohskopf,et al.  Prevention and control of seasonal influenza with vaccines. Recommendations of the Advisory Committee on Immunization Practices--United States, 2013-2014. , 2013, MMWR. Recommendations and reports : Morbidity and mortality weekly report. Recommendations and reports.

[41]  J. Noh,et al.  Long‐term and cross‐reactive immunogenicity of inactivated trivalent influenza vaccine in the elderly: MF59‐adjuvanted vaccine versus unadjuvanted vaccine , 2013, Journal of medical virology.

[42]  C. Hannoun,et al.  The evolving history of influenza viruses and influenza vaccines , 2013, Expert review of vaccines.

[43]  M. Loeb,et al.  Safety, immunogenicity, and tolerability of three influenza vaccines in older adults , 2013, Human vaccines & immunotherapeutics.

[44]  Sang Il Kim,et al.  Immunogenicity and safety of Intanza®/IDflu® intradermal influenza vaccine in South Korean adults: A multicenter, randomized trial , 2013, Human vaccines & immunotherapeutics.

[45]  C. Diazgranados,et al.  High-dose trivalent influenza vaccine compared to standard dose vaccine in elderly adults: safety, immunogenicity and relative efficacy during the 2009-2010 season. , 2013, Vaccine.

[46]  F. Ansaldi,et al.  Head-to-head comparison of an intradermal and a virosome influenza vaccine in patients over the age of 60 , 2013, Human vaccines & immunotherapeutics.

[47]  K. Richardson,et al.  A Meta‐analysis of intradermal versus intramuscular influenza vaccines: Immunogenicity and Adverse Events , 2012, Influenza and other respiratory viruses.

[48]  K. Rothman,et al.  Effectiveness of Adjuvanted Influenza Vaccination in Elderly Subjects in Northern Italy , 2012, American journal of epidemiology.

[49]  L. Sticchi,et al.  Antibody response against heterogeneous circulating influenza virus strains elicited by MF59- and non-adjuvanted vaccines during seasons with good or partial matching between vaccine strain and clinical isolates. , 2010, Vaccine.

[50]  P. van Damme,et al.  Evaluation of non-inferiority of intradermal versus adjuvanted seasonal influenza vaccine using two serological techniques: a randomised comparative study , 2010, BMC infectious diseases.

[51]  P. van Damme,et al.  Intradermal influenza vaccine for older adults: a randomized controlled multicenter phase III study. , 2009, Vaccine.

[52]  N. Groth,et al.  MF59-adjuvanted versus non-adjuvanted influenza vaccines: integrated analysis from a large safety database. , 2009, Vaccine.

[53]  A. Falsey,et al.  Randomized, double-blind controlled phase 3 trial comparing the immunogenicity of high-dose and standard-dose influenza vaccine in adults 65 years of age and older. , 2009, The Journal of infectious diseases.

[54]  R. Gasparini,et al.  Comparison between a conventional subunit vaccine and the MF59-adjuvanted subunit influenza vaccine in the elderly: an evaluation of the safety, tolerability and immunogenicity. , 2009, Journal of preventive medicine and hygiene.

[55]  F. de Looze,et al.  Intradermal influenza vaccine administered using a new microinjection system produces superior immunogenicity in elderly adults: a randomized controlled trial. , 2008, The Journal of infectious diseases.

[56]  L. Sticchi,et al.  Cross-protection by MF59-adjuvanted influenza vaccine: neutralizing and haemagglutination-inhibiting antibody activity against A(H3N2) drifted influenza viruses. , 2008, Vaccine.

[57]  H. Fang,et al.  Safety and immunogenicity of an MF59™-adjuvanted subunit influenza vaccine in elderly Chinese subjects , 2008, Immunity & Ageing.

[58]  I. D. de Bruijn,et al.  Antibody induction by virosomal, MF59-adjuvanted, or conventional influenza vaccines in the elderly. , 2007, Vaccine.

[59]  R. Couch,et al.  Safety and immunogenicity of a high dosage trivalent influenza vaccine among elderly subjects. , 2007, Vaccine.

[60]  M. Basileo,et al.  Influenza vaccination in patients on long-term anticoagulant therapy. , 2006, Vaccine.

[61]  R. Couch,et al.  Safety of high doses of influenza vaccine and effect on antibody responses in elderly persons. , 2006, Archives of internal medicine.

[62]  C. Ewen,et al.  T Cell Responses Are Better Correlates of Vaccine Protection in the Elderly1 , 2006, The Journal of Immunology.

[63]  Keiji Fukuda,et al.  Influenza-associated hospitalizations in the United States. , 2004, JAMA.

[64]  B. Ruf,et al.  Open, Randomized Study to Compare the Immunogenicity and Reactogenicity of an Influenza Split Vaccine with an MF59-Adjuvanted Subunit Vaccine and a Virosome-Based Subunit Vaccine in Elderly , 2004, Infection.

[65]  L. Biasio,et al.  Comparison of the reactogenicity and immunogenicity of a split and a subunit-adjuvanted influenza vaccine in elderly subjects. , 2003, Vaccine.

[66]  Keiji Fukuda,et al.  Mortality associated with influenza and respiratory syncytial virus in the United States. , 2003, JAMA.

[67]  A. Floreani,et al.  Comparison of three different influenza vaccines in institutionalised elderly. , 2001, Vaccine.

[68]  F. Pregliasco,et al.  Immunogenicity and safety of three commercial influenza vaccines in institutionalized elderly , 2001, Aging.

[69]  M. Faccini,et al.  Safety and immunogenicity of MF59-adjuvanted influenza vaccine in the elderly. , 1999, Vaccine.

[70]  A. S. Beare,et al.  The role of serum haemagglutination-inhibiting antibody in protection against challenge infection with influenza A2 and B viruses , 1972, Epidemiology and Infection.

[71]  D. Nace,et al.  Randomized , Controlled Trial of High-Dose In fl uenza Vaccine Among Frail Residents of Long-Term Care Facilities , 2015 .

[72]  J. Higgins,et al.  Cochrane Handbook for Systematic Reviews of Interventions, Version 5.1.0. The Cochrane Collaboration , 2013 .

[73]  L. Sticchi,et al.  Cross-protection elicited by MF59-adjuvanted vaccine during seasons with good or partial matching between vaccine strain and clinical isolates , 2011 .

[74]  R. Gasparini,et al.  Increased immunogenicity of the MF59-adjuvanted influenza vaccine compared to a conventional subunit vaccine in elderly subjects , 2004, European Journal of Epidemiology.

[75]  A. Podda,et al.  Safety and immunogenicity of an inactivated subunit influenza virus vaccine combined with MF59 adjuvant emulsion in elderly subjects, immunized for three consecutive influenza seasons. , 1999, Vaccine.

[76]  FRCP W. J. MacLennan MD,et al.  The Elderly , 1984, Treatment in Clinical Medicine.